within Pharmacolibrary.Drugs.ATC.G;

model G04CA52
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.9,
    Cl             = 0.00015333333333333334,
    adminDuration  = 600,
    adminMass      = 0.4 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.016,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0023333333333333335,
    Tlag           = 600,            
    Vdp             = 0.106,
    k12             = 40,
    k21             = 40
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>G04CA52</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Tamsulosin and dutasteride are medications combined for the treatment of benign prostatic hyperplasia (BPH) in men. Tamsulosin is an alpha-1 adrenergic antagonist that relaxes the muscles in the prostate and bladder neck, making it easier to urinate. Dutasteride is a 5-alpha reductase inhibitor that reduces the size of the prostate gland. The combination is used to improve urinary symptoms and is approved and widely used clinically.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameter estimates for adult male subjects with BPH, typical population parameters for tamsulosin and dutasteride combination therapy after oral administration.</p><h4>References</h4><ol><li><p>Ciríaco, SL, et al., &amp; Carvalho, ALM (2020). Development of microemulsion of tamsulosin and dutasteride for benign prostatic hyperplasia therapy. <i>Colloids and surfaces. B, Biointerfaces</i> 185 110573–None. DOI:<a href=&quot;https://doi.org/10.1016/j.colsurfb.2019.110573&quot;>10.1016/j.colsurfb.2019.110573</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/31675643/&quot;>https://pubmed.ncbi.nlm.nih.gov/31675643</a></p></li><li><p>Li, H, et al., &amp; Wang, C (2015). Effect of tamsulosin on the pharmacokinetics of dutasteride in Chinese male healthy volunteers. <i>Clinical pharmacology in drug development</i> 4(6) 427–433. DOI:<a href=&quot;https://doi.org/10.1002/cpdd.197&quot;>10.1002/cpdd.197</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/27137714/&quot;>https://pubmed.ncbi.nlm.nih.gov/27137714</a></p></li><li><p>Piñeyro-Garza, E, et al., &amp; Delgado-Roche, L (2022). Bioequivalence Assessment of an Oral Fixed-Dose Formulation of Dutasteride-Tamsulosin 0.5 mg/0.4 mg: A Randomized, Single-Blind, Single-Dose, 2-Period Crossover Study in Mexican Population Under Fasted Conditions. <i>Clinical pharmacology in drug development</i> 11(3) 318–323. DOI:<a href=&quot;https://doi.org/10.1002/cpdd.1011&quot;>10.1002/cpdd.1011</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/34384000/&quot;>https://pubmed.ncbi.nlm.nih.gov/34384000</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end G04CA52;
